West Pharmaceutical Services (WST) Net Margin (2009 - 2026)

West Pharmaceutical Services has disclosed Net Margin across 18 years of filings, most recently posting 16.03% for Q1 2026.

• Net Margin for Q1 2026 came in at 16.03%, up 365.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 16.4% (up 74.0% YoY), and the FY2025 annual result was 15.59%, down 93.0% from the prior year.
• Net Margin came in at 16.03% for Q1 2026 at West Pharmaceutical Services, up from 15.93% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 23.73% in Q2 2022 to a low of 12.38% in Q1 2025.
• The 5-year median for Net Margin is 17.11% (2024), against an average of 17.63%.
• Across the five-year window, Net Margin plunged 708 bps in 2022 and surged 423 bps in 2023, its largest moves.
• West Pharmaceutical Services' Net Margin stood at 14.08% in 2022, then grew by 30 bps to 18.27% in 2023, then retreated by 6 bps to 17.11% in 2024, then decreased by 7 bps to 15.93% in 2025, then rose by 1 bps to 16.03% in 2026.
• The last three Net Margin figures came in at 16.03% (Q1 2026), 15.93% (Q4 2025), and 17.14% (Q3 2025), per Business Quant data.